Prezcobix (Darunavir/Cobicistat) Patent Expiration, LOE Window & CMS Spending
Prezcobix (Darunavir/Cobicistat) by Johnson & Johnson: FDA Orange Book core substance LOE 2029-09-03 (last listed 2032-10-06), 0 AB generics, $353.1M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N205395 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2029-09-03 |
| Last Listed Patent or Exclusivity Date | 2032-10-06 |
| Orange Book Patents (*PED Extensions) | 4 patents (1 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $353.1M |
| 2024 Medicare Part D Spend | $255.4M |
| 2024 Medicaid Spend | $97.7M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 18.7% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.